Am­gen tees up a swift ap­proval for a fran­chise de­stroy­er aimed at Ab­b­Vie’s $14B drug Hu­mi­ra

The FDA wast­ed lit­tle time in com­ing to the point in their re­view of Am­gen’s ap­pli­ca­tion for ABP501, their new biosim­i­lar of Ab­b­Vie’s megablock­buster in­flam­ma­to­ry drug Hu­mi­ra: They got it right.

“In con­sid­er­ing the to­tal­i­ty of the ev­i­dence, the da­ta sub­mit­ted by Am­gen sup­port a demon­stra­tion that ABP 501 is high­ly sim­i­lar to US-li­censed Hu­mi­ra, notwith­stand­ing mi­nor dif­fer­ences in clin­i­cal­ly in­ac­tive com­po­nents, and sup­port a demon­stra­tion that there are no clin­i­cal­ly mean­ing­ful dif­fer­ences be­tween ABP 501 and US-li­censed Hu­mi­ra in terms of the safe­ty, pu­ri­ty, and po­ten­cy of the prod­uct to sup­port the demon­stra­tion that ABP 501 is biosim­i­lar to the US-li­censed Hu­mi­ra in the stud­ied in­di­ca­tions of RA and PsO,” the agency notes in their ex­ec­u­tive re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER